Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. - Wikidata - wikimedia - TriplyDB

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

http://www.wikidata.org/entity/Q36660669

about

Targeted therapies and immunotherapy in non-small-cell lung cancer Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations Somatic DNA mutation analysis in targeted therapy of solid tumours The Evolution of Therapies in Non-Small Cell Lung Cancer Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer.Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations Drug resistance missense mutations in cancer are subject to evolutionary constraints Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR Beyond histology: translating tumor genotypes into clinically effective targeted therapies.Systems biology approaches to develop innovative strategies for lung cancer therapy.The quest to overcome resistance to EGFR-targeted therapies in cancer.Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.KPT-330 has antitumour activity against non-small cell lung cancer.Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinoma Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations Novel agents in development for advanced non-small cell lung cancer.Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.

P2860

Q26738986-1239794C-3076-4804-90F8-35905CF07328 Q26744339-CB4B5135-5992-4E92-B918-0DCBD3FBA909 Q26770324-00922AD2-FD7F-4F2A-9A89-AE07D099A469 Q26786932-B6B084C8-84DA-421E-BEA9-3ACBDF1711BE Q26826437-D3A1DC70-A8E3-4D64-8FFC-62D3BCDE11CA Q26865779-868FBCD9-6A65-4559-997B-E9DF2F923836 Q27013006-D21B23E6-2120-493A-806E-B07154BFD2FE Q27345313-9066BD0D-5D6C-468A-A4A3-AA708AE4CE76 Q27852553-9E33A374-BD6D-4536-94F8-CEF18668CBFE Q27852979-45527A9F-9386-4D71-A914-AEE9906AF714 Q27853339-83260EED-83A5-4074-A3ED-EE7D686E0E88 Q28077504-AB927415-7815-4E5E-B93E-844A296AB41F Q28079320-904C66FA-83DE-4494-A961-FD8DBA44D2C3 Q28083239-8111D413-2479-4069-ADEF-E34B5408BF0B Q28259999-15294ED3-3033-47D6-ADD6-85B0F9DD31C2 Q28384015-BF6EEF87-A387-44EA-88C2-DB08BD5B7754 Q28537830-E9BB4C18-0465-4941-B008-7A4C5DA6C4D4 Q28537922-BCA96D2C-D106-4883-8260-42F280CF5C6A Q30850656-E4BB9873-9AA6-4FE0-A589-4F6426E905C5 Q33276057-40675C85-C0BF-4624-8853-5EFB83840274 Q33560928-EDD3D947-BA6F-43B7-A5DE-5AAA3594E666 Q33720233-DA73F124-AB14-431F-8932-4BB85D5844EC Q33725976-9014D20A-FA61-4DE9-989F-2E03A2A825AE Q33736664-FBBB8EA9-038E-4EB5-AC39-42D3E1820D73 Q33787355-EFF7F648-E176-41A4-8BE1-95E29A3D55EE Q33819404-D6545B55-4DED-4EFD-A0D6-A8F8DB7EA6D3 Q33829794-A23B3301-8536-4E5F-ADDB-C623048A3DD9 Q33873274-EE066C50-DE68-4CA6-BAF4-11B7B82B5720 Q33918079-8E6F1F81-8CC3-4EF6-9EC4-F7CBEB6C6B00 Q33938441-A5EB044F-EDB6-4A87-9B4B-2DFA5D39BE68 Q33948614-AED0D407-1830-4189-990D-46B2AE10640A Q33995206-FB125A3A-71A0-4AD4-B2DA-1D396B3B0AC6 Q34041761-1DC48842-BAC9-432F-B31E-122BEA63AF85 Q34103108-731AE594-3B21-4558-A138-BC4DD16028B9 Q34117589-0758C81D-93F6-40B1-869D-40AA00260664 Q34135471-14C993C7-5874-40BC-942C-067AE08863D6 Q34389263-4E24D015-4230-4BC8-B1EA-0948306C2E76 Q34392733-167C0CC9-15BF-49FA-BBB5-2FA6A977B42B Q34996125-EBCA4A5B-301C-45BC-9A93-B3C8B45D4129 Q35112467-1A0C2C2A-DFAD-4C65-A44D-B995BB9187FB

P2860

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

http://www.wikidata.org/entity/Q36660669

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

@ast

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

@en

type

label

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

@ast

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

@en

prefLabel

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

@ast

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

@en

P1433

Q36660669-EE2AF631-48F4-4BF7-B1D7-6714046D86F3

P1476

Q36660669-CF62EB04-7EBB-44C5-A46E-BE395ED24121

P2093

Q36660669-036CCA7C-B1D4-4D78-8084-3A6FA9489186

Q36660669-94D7EBCA-1CBE-46A6-AF56-D180AF2F29BE

Q36660669-DA6A72CF-7177-47AC-BA34-D7F5164B5F34

P2860

Q36660669-00841199-83E5-4472-B767-3CB216835331

Q36660669-0206D39A-785D-463A-845B-BA6CC59BB17A

Q36660669-02A5C77E-66DB-4E63-832D-B04A3D0D2C6D

Q36660669-03355202-442F-4FA4-85B2-D1EA9730F964

Q36660669-03AC8A99-6EA9-42D2-872A-8C5AACECF0C4

Q36660669-07CC8542-79FD-4B91-86BE-7C90E8F92C58

Q36660669-086740C2-580B-4BF6-AA50-60AC06198D57

Q36660669-0AB43C34-2085-4444-872B-60411625F557

Q36660669-0F140123-C4E2-4CBB-AB41-26E087FBB805

Q36660669-0F428EBB-DAF0-4A13-8EEF-2A67E5FEA3DD

P304

Q36660669-1835572A-2CE2-4157-B2BB-91124C284C84

P31

Q36660669-104660C1-D563-423F-8A03-BA2D1F654AB9

P356

Q36660669-B5747853-18C8-47D3-955D-D6A115AE7C92

P407

Q36660669-52B1E5B9-A1BC-44E9-92CA-C8AA0876FF67

P433

Q36660669-008E0B83-F256-4CBC-91EF-0B6CE960214E

P478

Q36660669-C0BC08FA-B076-4FC4-B36A-78AC4F6EA687

P50

Q36660669-B6D82C6C-FE38-4A4D-9ECE-D3FC9FD33333

P577

Q36660669-C74B19E0-94C0-449D-9114-50F685BDE50C

P698

Q36660669-44132E6E-B578-41AD-BA6B-F9563FDA1760

P932

Q36660669-295CE08C-A5FC-4D54-A764-E634DEAE0BF8

P356

JCO.2012.43.3912

P1433

Journal of Clinical Oncology

P1476

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

@en

P2093

Franziska Michor

http://www.w3.org/2001/XMLSchema#string

Kadoaki Ohashi

http://www.w3.org/2001/XMLSchema#string

Yosef E Maruvka

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

P304

1070-1080

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.43.3912

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23401451

http://www.w3.org/2001/XMLSchema#string

P932

3589701

http://www.w3.org/2001/XMLSchema#string